SCA
NVO

Sandy Cove Advisors’s Novo Nordisk NVO Stock Holding History

Sandy Cove Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-786
Closed -$44K – 283
2022
Q1 		$44K Hold
786
– – 0.04% 216
2021
Q4 		$44K Buy
+786
New +$42.6K 0.04% 207

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sandy Cove Advisors's NVO Position: Q2 2022 in Review

Sandy Cove Advisors sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 786 shares — an estimated $44K sold.

Sandy Cove Advisors first reported a position in NVO in Q4 2021 and held it in 2 quarters. The position peaked at $44K in Q1 2022. 933 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

  • Sandy Cove Advisors reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
  • Sandy Cove Advisors sold 786 Novo Nordisk shares in Q2 2022, an estimated $44K.
  • Sandy Cove Advisors first reported a position in Novo Nordisk in Q4 2021 and held it in 2 quarters.
  • Sandy Cove Advisors's Novo Nordisk position peaked at $44K in Q1 2022.
  • 933 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.